Tumor-feeding hepatic microvasculature

The tumor-feeding hepatic microvasculature refers to the specialized network of blood vessels, primarily derived from the hepatic artery, that supplies oxygen and nutrients to malignant liver tumors such as hepatocellular carcinoma (HCC) (StatPearls: Hepatocellular Carcinoma). Unlike healthy liver tissue, which receives the majority of its blood supply from the portal vein, hypervascular liver tumors rely almost exclusively on arterial flow for growth and survival (PubMed: PMID 12623477). This physiological distinction allows for targeted locoregional therapies, such as transarterial chemoembolization (TACE), which involves the delivery of chemotherapeutic agents and embolic materials directly into these feeding vessels to induce tumor ischemia and necrosis (NIH: Liver Cancer Treatment). Furthermore, this microvasculature is a key site for the action of systemic anti-angiogenic agents like Sorafenib and Lenvatinib, which inhibit the vascular endothelial growth factor (VEGF) pathway to disrupt tumor-associated angiogenesis (PubChem: Sorafenib). The architecture of these vessels is often disorganized, characterized by leaky endothelium and high interstitial pressure, which can impede the delivery of systemic therapies (PubMed: PMID 15141214). Therapeutic challenges include the risk of post-embolization syndrome, characterized by pain and fever, and potential damage to non-tumorous liver tissue due to the complex and often aberrant nature of the hepatic vascular anatomy (StatPearls: TACE).

Other names

Tumor-associated hepatic vasculatureHepatic tumor microvesselsTumor-feeding arteriesTumor-feeding vessels

Inhibition of angiogenesis via VEGF/PDGF/FGF pathway blockade and physical occlusion of blood flow (embolization) to induce ischemic necrosis.